causal

Sample Denial Blocks Bioequivalence Testing

Brand companies can block generics by refusing to sell them a sample needed to prove bioequivalence, restricting distribution to certain pharmacies or hospitals or invoking REMS safety protocols to claim the generic isn't a qualified buyer—and even when the FDA says transfer is fine, the brand can refuse, leaving the parties in a standoff that keeps the generic off the market.

causalpending

Speaker

Robin Feldman

Evidence Quote

“if the Brand-name company won't sell me the sample, I can't do that.”

Source

Robin Feldman on Drug Patents, Generics, and Drug Wars— EconTalk
Created: 6/13/2026, 12:11:23 AM

Your notes

Loading notes...